Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

• click to rate

  Posted by Two Blokes Jul 11 - Filed in Stock - 8 views
  
  Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable